

**PRESS RELEASE**

**NOTIFICATION PURSUANT TO ARTICLE 17 OF THE AIM ITALIA ISSUERS REGULATIONS**

Pisa, 16<sup>th</sup> April 2019 – Pharmanutra S.p.A. (“**Pharmanutra**” or “**PHN**”) gives notice, in compliance with the Transparency Directive and article 17 of the AIM Italia Issuer Regulations, to have received on the 16<sup>th</sup> April 2019 from Andrea Lacorte, Roberto Lacorte, Beda S.r.l, Gianni Lazzarini and COFIRCONT Compagnia Fiduciaria S.r.l. (such trust company designated and charged by Andrea Lacorte and Roberto Lacorte with specific trustee mandates) notification regarding changes made on the 16<sup>th</sup> April 2019 of the major shareholdings held respectively by the above parties in PHN as follows:

- (i) Andrea Lacorte, declared a holding of 3,118,334 PHN ordinary shares, equal to 32.21% of the relative share value with voting rights, of which 950,000 shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate;
- (ii) Roberto Lacorte, declared a holding of 2,318,833 PHN ordinary shares, equal to 23.95% of the relative share capital with voting rights, of which 950,000 shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate;
- iii) Beda S.r.l., declared a holding of 1,094,993 PHN ordinary shares, equal to 11.31% of the relative share capital with voting rights.

Gianni Lazzarini instead notified a reduction in his PHN stake to within the major threshold of 5% of the share capital.

On the basis of the notification received from the shareholders and the information currently available to the Company, the shareholders that hold a stake of over 5% of the share capital with Pharmanutra voting rights are therefore the following:

SHAREHOLDER	OWNERSHIP TITLE	NUMBER OF SHARES WITH VOTING RIGHTS HELD	% ON THE SHARE CAPITAL WITH VOTING RIGHT
Andrea Lacorte	Owner	3,118,334 <sup>(1)</sup>	32,21
Roberto Lacorte	Owner	2.318.833 <sup>(2)</sup>	23,95
Beda S.r.l. <sup>(3)</sup>	Owner	1.094.993	11,31

<sup>(1)</sup> Of which 950,000 PHN ordinary shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate.

<sup>(2)</sup> Of which 950,000 PHN ordinary shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate.

<sup>(3)</sup> It should be noted that Carlo Volpi is sole shareholder and sole director of Beda S.r.l.

It is notified that, in compliance with the article 26 of the AIM Italia Issuer Regulations, the names of the PHN major shareholders are also available on the company’s website ([www.pharmanutra.it](http://www.pharmanutra.it) / Sezione “Investors - [Capitale Sociale e Azionariato](#)”).

**PharmaNutra S.p.A.**

*Founded and guided by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra was established in 2003 and develops unique nutraceutical supplements and innovative nutritional devices, handling the entire production process, from the proprietary raw materials to the finished product. The effectiveness of its products has been demonstrated by numerous clinical studies, 91 of which have been published the involvement of over 6,000 patients. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents for sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

<http://www.PharmaNutra.it>

\*\* \*\*\* \*\*

*For Information:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b

56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Nomad & Specialist

**CFO SIM S.p.A.**

Via dell'Annunciata 23/4

20121 Milan

Tel. +39 02 303431

[ecm@cfosim.com](mailto:ecm@cfosim.com)

Press Office

**Spriano Communication&Partners**

Tel. +39 02 83635708

Matteo Russo - Cristina Tronconi

Mob. +39 347 9834881 +39 346 0477901

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)